Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

  1. 30 Αυγ 2024 · ESC Clinical Practice Guidelines aim to present all the relevant evidence to help physicians weigh the benefits and risks of a particular diagnostic or therapeutic procedure on Atrial Fibrillation. They should be essential in everyday clinical decision making.

  2. Gerhard Hindricks, University Clinic of Cardiology, Heart Center Leipzig, Department of Cardiology and Electrophysiology, Leipzig Heart Institute, Stru¨mpellstr. 39, 04289 Leipzig, Germany. Tel: þ49 34 1865 1410, Fax: þ49 34 1865 1460, Email: gerhard.hindricks@helios-gesundheit.de

  3. 30 Νοε 2023 · In addition, new recommendations addressing atrial fibrillation and thromboembolic risk assessment, anticoagulation, left atrial appendage occlusion, atrial fibrillation catheter or surgical ablation, and risk factor modification and atrial fibrillation prevention have been developed.

  4. 30 Ιουν 2022 · Atrial fibrillation is the most common heart rhythm disorder (affecting approximately 2% of the adult population), and estimates suggest its prevalence is increasing. Atrial fibrillation causes palpitations and breathlessness in many people but it may be silent and undetected.

  5. regular pattern. Atrial fibrillation (AF) is one type of ar-rhythmia. AF occurs when the upper chambers of the heart (the atria) fibrillate, or “quiver,” which causes a rapid, irregular heart rhythm. The normal heart rate for an adult is between 60 and 100 beats every minute. When the heart is in AF, the atria can beat over 300 times every ...

  6. This guideline is to guide the management of patients presenting with atrial fibrillation across all clinical areas within the trust. In the majority of cases atrial flutter is treated in the same way as atrial fibrillation with regards to the options for rate control, rhythm control and anticoagulation. 2. Flow Charts

  7. 28 Μαρ 2014 · For patients with AF or atrial flutter of 48 hours’ duration or longer or when duration of AF is unknown, anticoagulation with dabigatran, rivaroxaban, or apixaban is reasonable for at least 3 weeks before and 4 weeks after cardioversion.115–117 (Level of Evidence: C) Class IIb. 1.